Salem Investment Counselors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.8M Sell
176,330
-42
-0% -$4.92K 0.57% 36
2026
Q1
$21.3M Sell
176,372
-12,111
-6% -$1.4M 0.63% 31
2025
Q4
$20M Sell
188,483
-1,165
-0.6% -$109K 0.56% 37
2025
Q3
$16.1M Sell
189,648
-3,052
-2% -$251K 0.46% 41
2025
Q2
$15.4M Sell
192,700
-63,710
-25% -$5.06M 0.49% 42
2025
Q1
$23.2M Buy
256,410
+761
+0.3% +$71.1K 0.81% 27
2024
Q4
$25.6M Buy
255,649
+2,278
+0.9% +$235K 0.84% 24
2024
Q3
$28.9M Buy
253,371
+777
+0.3% +$92.3K 0.87% 22
2024
Q2
$31.4M Buy
252,594
+2,702
+1% +$348K 1.01% 18
2024
Q1
$33.1M Buy
249,892
+5,302
+2% +$654K 1.09% 18
2023
Q4
$26.8M Buy
244,590
+5,348
+2% +$555K 0.92% 20
2023
Q3
$24.8M Buy
239,242
+1,790
+0.8% +$193K 0.94% 20
2023
Q2
$27.6M Buy
237,452
+1,012
+0.4% +$115K 1% 16
2023
Q1
$25.3M Sell
236,440
-4,095
-2% -$442K 1.01% 17
2022
Q4
$26.8M Buy
240,535
+3,140
+1% +$321K 1.15% 12
2022
Q3
$20.6M Sell
237,395
-2,657
-1% -$237K 0.94% 18
2022
Q2
$22M Buy
240,052
+3,749
+2% +$332K 1% 15
2022
Q1
$19.4M Sell
236,303
-72
-0% -$5.68K 0.76% 24
2021
Q4
$18.1M Sell
236,375
-14,467
-6% -$1.15M 0.63% 26
2021
Q3
$18.8M Buy
250,842
+5,212
+2% +$396K 1.03% 22
2021
Q2
$19.1M Sell
245,630
-2,345
-0.9% -$174K 1.05% 20
2021
Q1
$18.2M Buy
247,975
+15,084
+6% +$1.11M 1.12% 23
2020
Q4
$18.2M Buy
232,891
+6,610
+3% +$506K 1.2% 19
2020
Q3
$17.9M Buy
226,281
+479
+0.2% +$37.5K 1.37% 15
2020
Q2
$16.7M Sell
225,802
-414
-0.2% -$31.2K 1.41% 16
2020
Q1
$16.6M Buy
226,216
+304
+0.1% +$23.9K 1.72% 12
2019
Q4
$19.6M Buy
225,912
+2,243
+1% +$184K 1.62% 15
2019
Q3
$18M Buy
223,669
+649
+0.3% +$52K 1.65% 15
2019
Q2
$17.8M Sell
223,020
-1,552
-0.7% -$119K 1.65% 14
2019
Q1
$15.2M Buy
224,572
+809
+0.4% +$60.5K 1.55% 19
2018
Q4
$16.3M Sell
223,763
-809
-0.4% -$57.1K 2.06% 12
2018
Q3
$15.2M Sell
224,572
-2,298
-1% -$146K 1.55% 19
2018
Q2
$13.1M Sell
226,870
-5,882
-3% -$332K 1.2% 21
2018
Q1
$12M Sell
232,752
-2,453
-1% -$132K 1.35% 22
2017
Q4
$12.6M Buy
235,205
+63,230
+37% +$3.51M 1.37% 22
2017
Q3
$10.6M Sell
171,975
-3,281
-2% -$199K 1.24% 23
2017
Q2
$10.7M Buy
175,256
+8,132
+5% +$495K 1.24% 23
2017
Q1
$10.1M Buy
167,124
+5,848
+4% +$355K 1.08% 30
2016
Q4
$9.06M Buy
161,276
+11,217
+7% +$656K 1.04% 31
2016
Q3
$89.4K Sell
150,059
-8,296
-5% -$485K 1.17% 28
2016
Q2
$8.71M Buy
158,355
+1,247
+0.8% +$66.4K 1.04% 30
2016
Q1
$7.93M Sell
157,108
-9,586
-6% -$469K 0.98% 32
2015
Q4
$8.4M Sell
166,694
-29,439
-15% -$1.48M 1.06% 31
2015
Q3
$9.16M Sell
196,133
-19,685
-9% -$1.05M 1.2% 22
2015
Q2
$11.7M Buy
215,818
+1,881
+0.9% +$105K 1.43% 16
2015
Q1
$11.7M Sell
213,937
-1,004
-0.5% -$56.8K 1.4% 16
2014
Q4
$11.6M Buy
214,941
+149
+0.1% +$8.3K 1.39% 17
2014
Q3
$12.2M Buy
214,792
+68
+0% +$3.82K 1.46% 15
2014
Q2
$11.9M Sell
214,724
-1,396
-0.6% -$76.2K 1.44% 16
2014
Q1
$11.7M Sell
216,120
-1,955
-0.9% -$101K 1.45% 17
2013
Q4
$10.4M Sell
218,075
-884
-0.4% -$40.4K 1.36% 19
2013
Q3
$9.95M Buy
218,959
+1,221
+0.6% +$55.7K 1.38% 21
2013
Q2
$9.65M Buy
+217,738
New +$9.73M 1.4% 18

Other funds holding MRK

Salem Investment Counselors's MRK Position: Q2 2026 in Review

Salem Investment Counselors reduced its Merck (MRK) stake by 0.02% in Q2 2026, selling an estimated $4.92K and leaving 176,330 shares worth $22.8M. The position accounts for 0.57% of the portfolio, ranked #36.

Salem Investment Counselors first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $33.1M in Q1 2024. 1,976 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Salem Investment Counselors held 176,330 shares of Merck worth $22.8M as of Q2 2026.
  • Salem Investment Counselors sold 42 Merck shares in Q2 2026, an estimated $4.92K.
  • Merck made up 0.57% of Salem Investment Counselors's portfolio in Q2 2026, its #36 holding.
  • Salem Investment Counselors first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Salem Investment Counselors's Merck position peaked at $33.1M in Q1 2024.
  • 1,976 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.